Author

Murray W Stewart

Observed names: M Stewart, M W Stewart, M. Stewart, M. W. Stewart, M. W. Stewart, M.W. Stewart, MURRAY STEWART, Murray Stewart, Murray W. Stewart

Institution: X4 Pharmaceuticals, Inc. (United States)

Observed institutions: GlaxoSmithKline (United Kingdom), Royal Victoria Infirmary, GlaxoSmithKline (United States), Rhythm (United states), X4 Pharmaceuticals, Inc. (United States), GlaxoSmithKline Research & Development Limited (United Kingdom), University of Glasgow, Newcastle University

OpenAlex ID: A5113581999

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

2018 · Adrian F Hernandez, Jennifer B Green, et al. · The Lancet · 1,822

PDF

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

2020 · Karine Clément, Erica van den Akker, et al. · The Lancet Diabetes & Endocrinology · 484

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

2014 · Richard E Pratley, Michael A Nauck, et al. · The Lancet Diabetes & Endocrinology · 324

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

2009 · Julio Rosenstock, Jane Reusch, et al. · Diabetes Care · 237

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

2014 · Bo Ahrén, Susan L. Johnson, et al. · Diabetes Care · 228

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

2014 · Julio Rosenstock, Vivian A. Fonseca, et al. · Diabetes Care · 211

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

2008 · Jessica E. Matthews, Murray W. Stewart, et al. · The Journal of Clinical Endocrinology & Metabolism · 198

PDF

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects

2009 · M. A. Bush, J. E. Matthews, et al. · Diabetes Obesity and Metabolism · 181

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

2014 · Peter N. Weissman, Molly C. Carr, et al. · Diabetologia · 135

PDF

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome

2020 · Robert Haws, Sheila Brady, et al. · Diabetes Obesity and Metabolism · 127

PDF

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

2015 · Michael A. Nauck, Murray W. Stewart, et al. · Diabetologia · 125

PDF

Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology

2006 · Ian M. Graham, Murray Stewart, et al. · European Journal of Cardiovascular Prevention & Rehabilitation · 116

Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide ( HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

2014 · J. Reusch, M. W. Stewart, et al. · Diabetes Obesity and Metabolism · 110

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5

2014 · P. D. Home, P. Shamanna, et al. · Diabetes Obesity and Metabolism · 101

Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid Retention

2006 · Janaka Karalliedde, Robin Buckingham, et al. · Journal of the American Society of Nephrology · 98

Rosiglitazone Improves Myocardial Glucose Uptake in Patients With Type 2 Diabetes and Coronary Artery Disease

2005 · Riikka Lautamäki, K.E. Juhani Airaksinen, et al. · Diabetes · 98

PDF

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

2014 · Lawrence A. Leiter, Molly C. Carr, et al. · Diabetes Care · 95

Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia.

1993 · M W Stewart, M F Laker, et al. · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 91

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study

2005 · Clifford J. Bailey, Alfredas Bagdonas, et al. · Clinical Therapeutics · 73

Features of Syndrome X in First-Degree Relatives of NIDDM Patients

1995 · Murray W Stewart, David B Humphriss, et al. · Diabetes Care · 66

Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families

1997 · D. B. Humphriss, M. W. Stewart, et al. · Diabetologia · 64

PDF

Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide

2022 · Martin Wabitsch, Sadaf Farooqi, et al. · Journal of the Endocrine Society · 62

PDF

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

2024 · Raffaele Badolato, Laia Alsina, et al. · Blood · 57

PDF

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

2003 · Zsuzsa Kerenyi, Holger Samer, et al. · Diabetes Research and Clinical Practice · 52

7-ketocholesterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin dependent diabetes and peripheral vascular disease

1997 · Robert G. Dyer, Murray W. Stewart, et al. · Clinica Chimica Acta · 51

Works count: 76

Citation count: 6,389

H-index: 33

I10-index: 53